Scientists at Imperial College London and teams at Oxford University are racing to adapt rapid vaccine platforms to tackle recent Ebola threats, using
Scientists at Imperial College London and teams at Oxford University are racing to adapt rapid vaccine platforms to tackle recent Ebola threats, using technologies that proved pivotal during the COVID‑19 pandemic.
Imperial’s EML‑Vac programme is preparing first‑in‑human trials of three self‑amplifying RNA (saRNA) vaccines targeting Ebola, Marburg and Lassa; the study will test safety and immune responses in healthy volunteers at Chelsea and Westminster Hospital, with recruitment already underway.
Separately, researchers at Oxford report that a viral‑vector vaccine (based on the ChAdOx1 platform) tailored to a new Bundibugyo Ebola strain could be ready for clinical testing in two to three months, pending completion of animal studies and regulatory clearances.
The ChAdOx1 approach is modular and can be rapidly retooled to match different viral glycoproteins, which shortens the timeline from sequence to candidate vaccine compared with traditional methods.
If early human trials confirm safety and immune responses, these candidates could move quickly into larger efficacy studies or ring‑vaccination campaigns in affected areas.
Public‑health experts caution that “ready for trials” is not the same as ready for deployment: trials must first demonstrate safety and immunogenicity, regulators must approve expanded testing, and manufacturing and distribution plans must be scaled for outbreak response.
For Ghana and neighbouring countries, the immediate priorities are surveillance, rapid case detection, and coordination with the WHO and the African CDC so that any successful vaccine can be evaluated and, if appropriate, deployed under emergency protocols.
Health ministries should also review cold‑chain capacity and community engagement strategies now so that, should trial results prove promising, vaccination campaigns can begin without delay.
COMMENTS